Disturbo di Ansia Generalizzato

Bibliografia

Quali fonti bibliografiche considerare per il Disturbo di Ansia Generalizzato?

Le informazioni contenute nella ricerca Pharmamedix dedicata alla criptosporidiosi sono state analizzate dalla redazione scientifica con riferimento alle seguenti fonti.

1. Akhondzadeh S. et al., J. Clin. Pharm. Ther., 2001, 26 (5), 363.


2. Allgulander C. et al., Int. J. Neuropsychopharmacol., 2006, 9 (5), 495.


3. Alonso J. et al., Acta Psychiatr. Scand. Suppl., 2004, 420, 55.


4. Amsterdam J.D. et al., J. Altern. Complement. Med., 2020, 26 (9), 813.


5. Ansseau M. et al., Neuropsychobiology, 1990, 24 (2), 74.


6. Armbrecht E. et al., J. Multidiscip. Healthc., 2021, 14, 887.


7. Ball S.G. et al., J. Clin. Psychiatry, 2005, 66 (1), 94.


8. Beesdo K. et al., J. Anxiety Disord., 2009, 23 (8), 1064.


9. Bielski R.J. et al., Ann. Clin. Psychiatry, 2005, 17 (2), 65.


10. Bohm C. et al., J. Clin. Psychopharmacol., 1990, 10 (3 Suppl.), 38S.


11. Bose A. et al., Depress. Anxiety, 2008, 25 (10), 854.


12. Brook J.S. et al., Addict. Behav., 2016, 62, 114.


13. Buoli M et al., Expert. Opin. Drug Metab. Toxicol., 2017, 13 (3), 351.


14. Buoli et al., Expert. Opin. Pharmacother., 2017a, 18 (13), 1373.


15. Boyer P. et al., Eur. Psychiatry, 2004, 19 (5), 272.


16. Cardoner N. et al., Front. Pharmacol., 2025, 7, 16.


17. Christensen H. et al., J. Med Internet Res., 2014, 16 (9), e199.


18. Davidson J.R. et al., J. Clinic. Psychiatry, 1999, 60 (8), 528.


19. Davidson J.R.T. et al., Depress. Anxiety, 2004, 19 (4), 234.


20. Davidson J.R.T. et al., J. Clin. Psychiatry, 2005, 66 (11), 1441.


21. Delle Chiaie R. et al., J. Clin. Psychopharmacol., 1995, 15 (1), 12.


22. Diagnostic and Statistical manual of Mental Disorders, Fifth Edition – DSM-5, 2013.


23. Diagnostic and Statistical manual of Mental Disorders, Fifth Edition, Text Revision - DSM-5 TR, 2022.


24. Durham P.C. et al., Psychol. Med., 2003, 33 (3), 499.


25. Enkelmann R., Psychopharmacology (berl), 1991, 105 (3), 428.


26. Faustino T.T. et al., Braz. J. Psychiatry, 2010, 32 (4), 429.


27. Feighner J.P., J. Clin. Psychiatry, 1987, 48 Suppl., 3.


28. Feltner D. et al., Int. Clin. Psychopharmacol., 2008, 23 (1), 18.


29. Fuladi S. et al., Curr. Rev. Clin. Exp. Pharmacol., 2021, 16 (2), 191.


30. Gammans R.E. et al., Neuropsychobiology, 1992, 25 (4), 193.


31. Gelabert R.Z., Altern. Integr. Med., 2017, 6, 4.


32. Gelenberg A.J. et al., JAMA, 2000, 283 (23), 3082.


33. Generoso M.B. et al., Int. Clin. Psychopharmacol., 2017, 32 (1), 49.


34. Haller et al., BMC Psychiatry, 2014 14, 128.


35. Haskins J.T. et al., Eur. Neuropsychopharmacol., 1998, 8 (Suppl. 2), S257.


36. Haskins J.T. et al., Eur. Neuropsychopharmacol., 1998a, 8 (Suppl. 2), S265.


37. Hood S.D. et al., Int. Clin. Psychopharmacol., 2025, 40 (2), 62.


38. Jin Y.J., Park J., Soa Chongsonyon Chongsin Uihak., 2024, 35 (4), 258.


39. Judd L.L. et al., Acta Psychiatrica Scand., 1998, (Suppl. 393), 6.


40. Kasper S. et al., Int. J. Neuropsychopharmacol., 2014, 17 (6), 859.


41. Khan A. et al., Ann. Clin. Psychiatry, 2014, 26 (1), 3.


42. Kreys T.J.M., Phan S.V., Pharmacotherapy, 2015, 32 (5), 175.


43. Lenze E.J. et al., JAMA, 2009, 301 (3), 295.


44. Mackenzie C.S. et al., Am. J. Geriatr. Psychiatry, 2011, 19 (4), 305.


45. Maneeton N. et al., Drug Des. Devel. Ther., 2016, 10, 259.


46. Mao J.J. et al., Phytomedicine, 2016,23 (14, 1735.


47. Masci Walter, Omeopatia - Tradizione e attualità, 2003, Tecniche Nuove.


48. McClave A.K. et al., Addict. Behav., 2009, 34 (6-7), 491.


49. Mochcovitch M.D. et al., Clin. Drug. Investig., 2017, 37 (8), 737.


50. Moffitt T.E. et al., Arch. Gen. Psychiatry, 2007, 64 (6), 651.


51. Mojtabai R. et al., Am. J. Public Health, 2013, 103 (9), 1656.


52. Mokhber N. et al., Psychiatry Clin. Neurosci., 2010, 64 (2), 128.


53. Montgomery S. et al., Br. J. Psychiatry J. Ment. Sci., 2008, 193 (5), 389.


54. Moon Y., Woo H., Front Public Health., 2025, 12, 1504739.


55. Moorthi K., Radhika P., Indian J. Res. Homeopathy, 2023, 17 (1), 31.


56. Muller W.E. et al., Neurochem. Int., 2021, 143, 104899.


57. Munir S., Takov V., StatPearls, 2022, 17 October https://www.ncbi.nlm.nih.gov/books/NBK441870/


58. Mykletun A. et al., Eur. Psychiatry, 2008, 23 (2), 77.


59. Oai S.L. et al., J. Altern. Complement. Med., 2018, 24 (8), 770.


60. Pancheri P., Romiti R., J. Psychopathology, 2000, issue-3.


61. Parewa M. et al., Complement. Med. Res., 2021, 28 (5), 407.


62. Park S.M. et al., J. Affect. Disord., 2024, 362, 630.


63. Perna G. et al., Curr. Psychiatry Rep., 2016, 18 (3), 23.


64. Petracca A. et al., J. Clin. Psychiatry, 1990, 51 Suppl., 31.


65. Pollack M.H. et al., J. Clin. Psychiatry, 2001, 62 (5), 350.


66. Rickels K. et al., Am. J. Psychiatry, 2003, 160 (4), 749.


67. Rodriguez B.F. et al., J. Nerv. Ment. Dis., 2006, 194 (2), 91.


68. Ross C.A., Matas M., Can. J. Psychiatry, 1987, 32 (5), 351.


69. Ruscio A.M. et al., JAMA Psychiatry, 2017, 74 (5), 465.


70. Sarris J. et al., CNS Dugs, 2013, 27 (4), 301.


71. Scholten W.D. et al., J. Affect. Disord., 2013, 147 (1-3), 180.


72. Stein D.J. et al., J. Clin. Psychiatry, 2012, 73 (7), 1002


73. Stein D.J. et al., Eur. Neuropsychopharmacol., 2018, 28 (8), 970.


74. Stein D.J. et al., Adv. Ther., 2021, 38 (3), 1567.


75. Stocchi F. et al., J. Clin. Psychiatry, 2003, 64 (3), 250.


76. Strawn J.R. et al., J. Clin. Psychiaty, 2020, 81 (5), 20m13396.


77. Von Kanel R. et al., Brain Behav., 2021, 11 (4), e01997.


78. WHO - World Health Organisation, 1993, Research guidelines for evaluating the safety and efficacy of herbal medicines.


79. Xinyuan Li et al., PloS One, 2018, 13 (3), e0194501.


80. Zhang X. Et al., Transl. Psychiatry, 2015, 5 (3), e536.